-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Akebia Therapeutics (NASDAQ:AKBA) Earns Hold Rating From Analysts at StockNews.com
Akebia Therapeutics (NASDAQ:AKBA) Earns Hold Rating From Analysts at StockNews.com
StockNews.com initiated coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a research report report published on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company's stock.
Separately, HC Wainwright cut their price objective on shares of Akebia Therapeutics from $2.00 to $1.25 in a research report on Monday, May 16th. Seven research analysts have rated the stock with a hold rating, According to data from MarketBeat, Akebia Therapeutics currently has an average rating of Hold and an average target price of $1.75.
Get Akebia Therapeutics alerts:Akebia Therapeutics Stock Performance
NASDAQ AKBA opened at $0.38 on Friday. The company has a current ratio of 1.30, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51. The firm has a 50-day simple moving average of $0.40 and a 200 day simple moving average of $0.85. Akebia Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.35.
Akebia Therapeutics (NASDAQ:AKBA – Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.54. The firm had revenue of $126.76 million during the quarter, compared to analysts' expectations of $49.10 million. Akebia Therapeutics had a negative net margin of 55.04% and a negative return on equity of 197.12%. During the same quarter last year, the company earned ($0.51) earnings per share. As a group, research analysts forecast that Akebia Therapeutics will post -0.44 EPS for the current fiscal year.Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in AKBA. Point72 Hong Kong Ltd bought a new position in Akebia Therapeutics during the 4th quarter valued at about $30,000. BNP Paribas Arbitrage SA increased its holdings in Akebia Therapeutics by 123.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 90,540 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 50,066 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Akebia Therapeutics during the 1st quarter valued at approximately $39,000. Mirabella Financial Services LLP purchased a new stake in Akebia Therapeutics during the 1st quarter valued at approximately $40,000. Finally, MetLife Investment Management LLC grew its holdings in Akebia Therapeutics by 176.6% during the 1st quarter. MetLife Investment Management LLC now owns 85,186 shares of the biopharmaceutical company's stock valued at $61,000 after buying an additional 54,389 shares in the last quarter. 31.56% of the stock is owned by hedge funds and other institutional investors.
About Akebia Therapeutics
(Get Rating)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
Further Reading
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- It Could Be a September to Remember for These 3 Stocks
- Can Roblox Reverse its Falling Bookings Amid Rising Engagements
- Peak Inflation Sets the Bottom for Brinker International Stock
- Broadcom Bounces From Institutional Bottom
- Is Autozone A Buy Before Earnings Are Released?
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com initiated coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a research report report published on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company's stock.
斯托克新聞網在週日上午發佈的一份研究報告中對木通治療公司(納斯達克:AKBA-GET評級)的股票進行了報道。該經紀公司對這家生物製藥公司的股票發佈了持有評級。
Separately, HC Wainwright cut their price objective on shares of Akebia Therapeutics from $2.00 to $1.25 in a research report on Monday, May 16th. Seven research analysts have rated the stock with a hold rating, According to data from MarketBeat, Akebia Therapeutics currently has an average rating of Hold and an average target price of $1.75.
另外,在5月16日星期一的一份研究報告中,HC Wainwright將木通治療公司的股票目標價從2.00美元下調至1.25美元。根據MarketBeat的數據,七位研究分析師對該股的評級為持有,木通治療公司目前的平均評級為持有,平均目標價為1.75美元。
Akebia Therapeutics Stock Performance
木通治療公司股票表現
NASDAQ AKBA opened at $0.38 on Friday. The company has a current ratio of 1.30, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51. The firm has a 50-day simple moving average of $0.40 and a 200 day simple moving average of $0.85. Akebia Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.35.
納斯達克AKBA上週五開盤報0.38美元。該公司的流動比率為1.30,速動比率為1.15,債務權益比率為0.51。該公司的50日簡單移動均線切入位為0.40美元,200日簡單移動均線切入位為0.85美元。木通治療公司的12個月低點為0.30美元,12個月高位為3.35美元。
Institutional Inflows and Outflows
機構資金流入和流出
A number of hedge funds have recently added to or reduced their stakes in AKBA. Point72 Hong Kong Ltd bought a new position in Akebia Therapeutics during the 4th quarter valued at about $30,000. BNP Paribas Arbitrage SA increased its holdings in Akebia Therapeutics by 123.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 90,540 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 50,066 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Akebia Therapeutics during the 1st quarter valued at approximately $39,000. Mirabella Financial Services LLP purchased a new stake in Akebia Therapeutics during the 1st quarter valued at approximately $40,000. Finally, MetLife Investment Management LLC grew its holdings in Akebia Therapeutics by 176.6% during the 1st quarter. MetLife Investment Management LLC now owns 85,186 shares of the biopharmaceutical company's stock valued at $61,000 after buying an additional 54,389 shares in the last quarter. 31.56% of the stock is owned by hedge funds and other institutional investors.
多家對衝基金最近增持或減持了Akba的股份。Point72 Hong Kong Ltd在第四季度購買了木通治療公司的新頭寸,價值約30,000美元。法國巴黎銀行套利公司在第二季度增持了木通治療公司123.7的股份。法國巴黎銀行套利公司現在擁有90,540股這家生物製藥公司的股票,價值32,000美元,在上個季度額外購買了50,066股。GSA Capital Partners LLP在第一季度購買了Akebia Treeutics的新股份,價值約3.9萬美元。Mirabella Financial Services LLP在第一季度購買了Akebia治療公司的新股份,價值約為4萬美元。最後,大都會人壽投資管理有限責任公司在第一季度增持了木通治療公司的股份176.6%。大都會人壽投資管理有限責任公司現在擁有85,186股這家生物製藥公司的股票,價值61,000美元,上個季度又購買了54,389股。31.56%的股票由對衝基金和其他機構投資者持有。
About Akebia Therapeutics
木通治療公司簡介
(Get Rating)
(獲取評級)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
木通治療公司是一家生物製藥公司,專注於腎臟疾病患者治療藥物的開發和商業化。該公司的主要研究產品候選產品是vadustat,這是一種口服療法,正處於第三階段開發,用於治療依賴透析和非透析依賴的成年患者的慢性腎臟疾病(CKD)引起的貧血。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- It Could Be a September to Remember for These 3 Stocks
- Can Roblox Reverse its Falling Bookings Amid Rising Engagements
- Peak Inflation Sets the Bottom for Brinker International Stock
- Broadcom Bounces From Institutional Bottom
- Is Autozone A Buy Before Earnings Are Released?
- 免費獲取StockNews.com關於木通治療的研究報告(AKBA)
- 對於這三隻股票來説,這可能是一個值得記住的9月
- 在預訂增加的情況下,Roblox能否扭轉預訂量下降的局面
- 通脹峯值為布林克國際股票設定底部
- 博通從機構底部反彈
- AutoZone是在收益發布之前買入的嗎?
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受木通治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對木通治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧